All In Biotech

Drug Trial Radar · NCT06643260

A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Daily Piclidenoson (CF101) Administered Orally in Subjects With Moderate-to-Severe Plaque Psoriasis

Last checked: Nov 20, 2026Latest source record: Apr 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 705 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

705

Planned (sponsor's estimate)

Start

Jun 2025

Primary completion

Dec 2027

Study completion Jun 2028

Sponsor

Lead sponsor
Can-Fite BioPharmaIndustry
Sponsor type
Industry
First posted
Oct 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a double-blind, placebo-controlled study in adults with a diagnosis of moderate-to-severe chronic plaque psoriasis to test the efficacy and safety of piclidenoson in this patient population.

Conditions

  • Plaque Psoriasis

Interventions

  • piclidenosonDrug

    Piclidenoson is a selective A3AR agonist, supplied as tablets.

  • PlaceboDrug

    Inactive control

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects who achieve a Psoriasis Area and Severity Index (PASI) score response of ≥75% (PASI 75)Time frame: 16 weeks
  2. proportion of subjects who achieve a Static Physician's Global Assessment (sPGA) of 0 or 1 with at least a 2-point improvement from BaselineTime frame: 16 weeks
  3. Proportion of subjects who experience adverse eventsTime frame: 52 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.